The Senate Health, Education, Labor & Pensions Committee last night voted 13-9 to advance legislation that would reauthorize Food and Drug Administration user fee programs and modify the regulatory framework for laboratory developed tests. AHA last week urged lawmakers to consider certain changes to the LDT provisions to ensure continued access to these critical tests.  
 
The House last week passed its own bill (H.R. 7667) to reauthorize FDA user fee programs, which does not include the LDT provisions. Among other provisions, the House bill would include drugs on the FDA’s shortages list in a pilot program to designate advanced manufacturing technologies. 
 

Related News Articles

Chairperson's File
Public
This week brings the fourth week of the federal government shutdown as Congress has yet to pass legislation to fund the government. This shutdown is a bit…
Headline
The government shutdown is expected to continue into next week as the Senate is expected to adjourn Oct. 23 with no plans to vote this weekend. The chamber Oct…
Headline
The Senate Oct. 16 failed for a 10th time to advance the continuing resolution to extend government funding and end the ongoing shutdown. The chamber adjourned…
Chairperson's File
Public
There is a saying that is very timely for our field: A smooth sea never made a skilled sailor. As we head into the final months of 2025, hospitals and health…
Headline
The federal government shutdown is expected to continue into next week as the Senate adjourned Oct. 9 after failing to pass spending legislation; senators plan…
Headline
The AHA provided a statement of record to the Senate Special Committee on Aging for a hearing Oct. 8 on the pharmaceutical and medical device supply chains.…